Live
- DCA busts three quack clinics in Hyd, Jangaon and Mahabubnagar
- Man threatens to jump into lake if he doesn’t get divorced from his wife
- Vikram’s ‘Veera Dheera Sooran’ teaser: Laden with mass elements
- Tamil Nadu records 40.05 pc voting till 1 pm
- Sithara Entertainments announces ‘MAD Square;’ pooja ceremony held
- Google Unifies Hardware and Software Teams for Advanced AI Development
- Amit Shah Recalls Political Journey As He Files Nomination From Gandhinagar
- Political Furor Erupts Over Tragic Campus Murder In Karnataka
- Liver diseases in kids up due to junk food, sugar consumption
- Air India Suspends Tel Aviv Flights Amidst Middle East Tensions
Omicron BA2 subvariant spreading as EU nations lift Covid curbs: EMA
European Medicines Agency
Cases of Omicron BA2, a Covid-19 subvariant, are rising across the European Union (EU) as member nations were lifting restrictions, the European Medicines Agency (EMA) said.
Brussels: Cases of Omicron BA2, a Covid-19 subvariant, are rising across the European Union (EU) as member nations were lifting restrictions, the European Medicines Agency (EMA) said.
"While many EU countries are lifting restrictions, we notice that the infection rates are increasing again in some member states, partly because of the circulation of Omicron BA2, which seems to be more transmissible than other variants," Xinhua news agency quoted Marco Cavalieri, head of the EMA's strategy on biological health threats and vaccines, as saying to journalists here on Thursday.
What matters the most, he said, is how this increase in cases will stress the healthcare systems.
The EMA called non-vaccinated citizens to get jabbed as soon as possible, emphasizing that there are now five Covid-19 jabs authorised in the EU using different technologies.
"There is currently no evidence that immune response after vaccination is significantly different with Omicron BA2. Vaccines continue to offer high protection against hospitalization and death," he said.
The vaccines that have received conditional marketing authorisation from the EMA are those produced by Pfizer/BioNtech, Moderna, AstraZeneca, Janssen and Novavax.
